Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world experience in the first-line treatment of Acute Myeloid Leukemia with ven-aza: Optimizing venetoclax exposure for better outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMarta Isabel Pereira

Discussion

Loading...

Member takes

Overview

Real-world experience suggests optimizing venetoclax exposure may improve survival in acute myeloid leukemia, indicating effective approaches to manage neutropenia.

Key Points

  • The research aims to assess real-world treatment experiences with venetoclax in acute myeloid leukemia to optimize patient outcomes.
  • Analyzed data from patients treated with venetoclax and azacytidine, focusing on neutropenia incidence.
  • Included patients starting first-line treatment from January 2023 to January 2025, excluding specific combinations.
  • Examined person-cycles for treatment delays, dose-reductions, and G-CSF support usage.
  • 60% of patients presented with neutropenia at the beginning of treatment cycles.
  • Median overall survival reached 21.4 months; optimal venetoclax exposure led to positive outcomes.
  • On-demand G-CSF support was utilized for delayed cycles, highlighting a tactical approach to manage neutropenia.

Cite This Study

Marta Isabel Pereira (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d33fhttps://doi.org/10.1182/blood-2025-6971
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of venetoclax dosing on outcomes in AML: A single-center real-world study.2026
  2. 2Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients2026
  3. 3Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  4. 4Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study2025
  5. 5Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia2026